4Wong J, Brugger A, Khare A, et al. Suspensions for intravenous (IV) injection : a review of development, preclinical and clinical aspects [ J ]. Adv Drug Deliv Rev,2008,60 (8) :939 - 954. 被引量：1
5Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future[ J]. Adv Drug Deliv Rev,2001,47 (1) :3 -19. 被引量：1
6Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer[ J]. Ann Oncol,2006,17(8) :1 263 - 1 268. 被引量：1
7Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles [ J ] . J Control Release, 2008, doi: 10. 1016/j. jconrel. 2008.05. 010. 被引量：1
8Yi Y, Yoon HJ, Kim BO, et al. A mixed polymeric micellar formulation of itraconazole : Characteristics, toxicity and pharmacokinetics [ J ]. J Control Release,2007,117 ( 1 ) :59 - 67. 被引量：1
9Lindfors L, Skantze P, Skantze U, et al. Amorphous drug nanosus- pensions. 1. Inhibition of Ostwald ripening [ J ]. Langmuir,2006, 22(3) :906 -910. 被引量：1
10Lindfors L, Forssen S, Skantze P, et al. Amorphous drug nanosuspensions. 2. Experimental determination of bulk monomer concentrations [ J ]. Langmuir,2006,22 ( 3 ) :911 - 916. 被引量：1
